C Velati

Summary

Country: Italy

Publications

  1. ncbi request reprint [The European Network of Transfusion Medicine Societies (EuroNet-TMS)]
    C Velati
    Transfusion medicine and haematology, department of Sondrio, Azienda Ospedialiera della Valtellina e della Valchiavenna, 23100 Sondrio, Italie
    Transfus Clin Biol 11:255-6. 2004
  2. ncbi request reprint Impact of nucleic acid amplification technology (NAT) in Italy in the three years following implementation (2001-2003)
    C Velati
    Dipartimento di Medicina Trasfusionale ed Ematologia, Ospedale di Sondrio, Italy
    Euro Surveill 10:12-4. 2005
  3. ncbi request reprint Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003
    J Coste
    EFS Pyrénées Méditerranée Laboratoire de R and D, F 34000 Montpellier, France
    Vox Sang 88:289-303. 2005

Detail Information

Publications3

  1. ncbi request reprint [The European Network of Transfusion Medicine Societies (EuroNet-TMS)]
    C Velati
    Transfusion medicine and haematology, department of Sondrio, Azienda Ospedialiera della Valtellina e della Valchiavenna, 23100 Sondrio, Italie
    Transfus Clin Biol 11:255-6. 2004
  2. ncbi request reprint Impact of nucleic acid amplification technology (NAT) in Italy in the three years following implementation (2001-2003)
    C Velati
    Dipartimento di Medicina Trasfusionale ed Ematologia, Ospedale di Sondrio, Italy
    Euro Surveill 10:12-4. 2005
    ..Thus the final NAT yield for HCV is 1.79/106. The residual risk for HCV or HIV transmission by blood transfusion after NAT implementation is currently estimated to be extremely low in Italy...
  3. ncbi request reprint Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003
    J Coste
    EFS Pyrénées Méditerranée Laboratoire de R and D, F 34000 Montpellier, France
    Vox Sang 88:289-303. 2005